Need Assistance?
  • US & Canada:
    +
  • UK: +

PUMA BH3

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

PUMA BH3, a p53-upregulating modulator of apoptosis (PUMA) BH3 domain peptide, is a direct activator of Bak with Kd of 26 nM.

Category
Peptide Inhibitors
Catalog number
BAT-009333
Molecular Formula
C128H202N42O43S
Molecular Weight
3049.29
IUPAC Name
(4S)-4-amino-5-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid
Synonyms
Glu-Glu-Gln-Trp-Ala-Arg-Glu-Ile-Gly-Ala-Gln-Leu-Arg-Arg-Met-Ala-Asp-Asp-Leu-Asn-Ala-Gln-Tyr-Glu-Arg; L-alpha-glutamyl-L-alpha-glutamyl-L-glutaminyl-L-tryptophyl-L-alanyl-L-arginyl-L-alpha-glutamyl-L-isoleucyl-glycyl-L-alanyl-L-glutaminyl-L-leucyl-L-arginyl-L-arginyl-L-methionyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-leucyl-L-asparagyl-L-alanyl-L-glutaminyl-L-tyrosyl-L-alpha-glutamyl-L-arginine
Appearance
White Lyophilized Powder
Purity
≥95%
Density
1.5±0.1 g/cm3
Sequence
EEQWAREIGAQLRRMADDLNAQYER
Storage
Store at -20°C
Solubility
Soluble in DMSO
InChI
InChI=1S/C128H202N42O43S/c1-12-60(6)100(170-115(203)79(35-42-97(183)184)159-107(195)71(21-15-44-142-125(134)135)152-102(190)62(8)150-116(204)85(52-66-56-146-70-20-14-13-19-68(66)70)167-114(202)76(32-38-91(132)174)158-110(198)77(33-40-95(179)180)155-105(193)69(129)29-39-94(177)178)123(211)147-57-93(176)148-61(7)101(189)153-74(30-36-89(130)172)112(200)164-82(49-58(2)3)118(206)157-73(23-17-46-144-127(138)139)108(196)156-72(22-16-45-143-126(136)137)109(197)161-80(43-48-214-11)106(194)149-64(10)104(192)163-87(54-98(185)186)121(209)169-88(55-99(187)188)122(210)165-83(50-59(4)5)119(207)168-86(53-92(133)175)117(205)151-63(9)103(191)154-75(31-37-90(131)173)113(201)166-84(51-65-25-27-67(171)28-26-65)120(208)160-78(34-41-96(181)182)111(199)162-81(124(212)213)24-18-47-145-128(140)141/h13-14,19-20,25-28,56,58-64,69,71-88,100,146,171H,12,15-18,21-24,29-55,57,129H2,1-11H3,(H2,130,172)(H2,131,173)(H2,132,174)(H2,133,175)(H,147,211)(H,148,176)(H,149,194)(H,150,204)(H,151,205)(H,152,190)(H,153,189)(H,154,191)(H,155,193)(H,156,196)(H,157,206)(H,158,198)(H,159,195)(H,160,208)(H,161,197)(H,162,199)(H,163,192)(H,164,200)(H,165,210)(H,166,201)(H,167,202)(H,168,207)(H,169,209)(H,170,203)(H,177,178)(H,179,180)(H,181,182)(H,183,184)(H,185,186)(H,187,188)(H,212,213)(H4,134,135,142)(H4,136,137,143)(H4,138,139,144)(H4,140,141,145)/t60-,61-,62-,63-,64-,69-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,100-/m0/s1
InChI Key
VKRGYZZRTOSZRW-ZOUZRHFXSA-N
Canonical SMILES
CCC(C)C(C(=O)NCC(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCSC)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)N
1. BH3-Only Proteins Noxa and Puma Are Key Regulators of Induced Apoptosis
Rabih Roufayel, Khaled Younes, Ahmed Al-Sabi, Nimer Murshid Life (Basel). 2022 Feb 9;12(2):256. doi: 10.3390/life12020256.
Apoptosis is an evolutionarily conserved and tightly regulated cell death pathway. Physiological cell death is important for maintaining homeostasis and optimal biological conditions by continuous elimination of undesired or superfluous cells. The BH3-only pro-apoptotic members are strong inducers of apoptosis. The pro-apoptotic BH3-only protein Noxa activates multiple death pathways by inhibiting the anti-apoptotic Bcl-2 family protein, Mcl-1, and other protein members leading to Bax and Bak activation and MOMP. On the other hand, Puma is induced by p53-dependent and p53-independent apoptotic stimuli in several cancer cell lines. Moreover, this protein is involved in several physiological and pathological processes, such as immunity, cancer, and neurodegenerative diseases. Future heat shock research could disclose the effect of hyperthermia on both Noxa and BH3-only proteins. This suggests post-transcriptional mechanisms controlling the translation of both Puma and Noxa mRNA in heat-shocked cells. This study was also the chance to recapitulate the different reactional mechanisms investigated for caspases.
2. BH3-only proteins Puma and Beclin1 regulate autophagic death in neurons in response to Amyloid-β
Akash Saha, Suraiya Saleem, Ramesh Kumar Paidi, Subhas C Biswas Cell Death Discov. 2021 Nov 15;7(1):356. doi: 10.1038/s41420-021-00748-x.
Alzheimer's disease (AD) is characterized by accumulation of senile amyloid-β (Aβ) plaques and hyperphosphorylated tau tangles causing progressive loss of synapse and neuronal death. Out of the various neuron death modalities, autophagy and apoptosis are reported to be the major death paradigms in AD. However, how these two processes lead to neuronal loss is still inconspicuous. Here we report that under Aβ toxicity, aberrant autophagy is induced with inefficient autophagic flux in neurons. Simultaneous activation of both autophagy and apoptosis are seen in primary cortical neurons as well as in transgenic mice brains. We found that induction of autophagy by rapamycin is detrimental for neurons; whereas downregulation of Beclin1, an important autophagy inducing protein, provides significant protection in Aβ treated neuronal cells by blocking cytochrome-c release from the mitochondria. We further report that downregulation of Puma, a BH3-only pro-apoptotic protein, inhibits the induction of aberrant autophagy and also ameliorates the autophagy flux under the influence of Aβ. Notably, stereotactic administration of shRNAs against Puma and Beclin1 in adult Aβ-infused rat brains inhibits both apoptotic and autophagic pathways. The regulation of both of the death processes is brought about by the direct interaction between Puma and Beclin1 upon Aβ treatment. We conclude that both Beclin1 and Puma play essential roles in the neuronal death caused by the induction of aberrant autophagy in AD and targeting their interaction could be vital to understand the crosstalk of autophagy and apoptosis as well as to develop a potential therapeutic strategy in AD.
3. Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives
Shirin Hafezi, Mohamed Rahmani Cancers (Basel). 2021 Mar 14;13(6):1292. doi: 10.3390/cancers13061292.
The major form of cell death in normal as well as malignant cells is apoptosis, which is a programmed process highly regulated by the BCL-2 family of proteins. This includes the antiapoptotic proteins (BCL-2, BCL-XL, MCL-1, BCLW, and BFL-1) and the proapoptotic proteins, which can be divided into two groups: the effectors (BAX, BAK, and BOK) and the BH3-only proteins (BIM, BAD, NOXA, PUMA, BID, BIK, HRK). Notably, the BCL-2 antiapoptotic proteins are often overexpressed in malignant cells. While this offers survival advantages to malignant cells and strengthens their drug resistance capacity, it also offers opportunities for novel targeted therapies that selectively kill such cells. This review provides a comprehensive overview of the extensive preclinical and clinical studies targeting BCL-2 proteins with various BCL-2 proteins inhibitors with emphasis on venetoclax as a single agent, as well as in combination with other therapeutic agents. This review also discusses recent advances, challenges focusing on drug resistance, and future perspectives for effective targeting the Bcl-2 family of proteins in cancer.
Online Inquiry
Verification code
Inquiry Basket